Skip to main content
. 2021 Jan 29;21(4):305. doi: 10.3892/etm.2021.9736

Figure 1.

Figure 1

KRT15 expression in normal and BRCA tissues. (A) Comparison of KRT15 expression [log2(TPM+1)] between tumor and normal samples and (B) between tumor and paracancerous samples was analyzed. (C) ROC curve analysis of KRT15 expression. KRT15 expression exhibited good discriminative efficacy between tumor and non-tumor samples. (D) Pan-cancer analysis of the difference in KRT15 expression across 33 types of cancer between tumor and normal samples. ***P<0.001; ns, **P≥0.05. The abscissa presents the FPR and the ordinate the TPR. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma; KRT15, keratin 15; ROC, receiver operating characteristic; AUC, area under the ROC curve; TCGA, The Cancer Genome Atlas; TPM, transcripts per million reads; FPR, false-positive rate; TPR, true-positive rate; GTEx, genotype-tissue expression.